Tone mix
Week by week 52 weeks
Share of Omeros Corporation's 163 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Sep 28, 2026 · tone -99Inside the bitter father-son feud that unravelled the Omeros Bros seafood dynasty - as the tax office winds up the iconic Gold Coast eatery-118
- Week of Oct 20, 2025 · tone 0Omeros Sells Exclusive Global Rights for Drug Zaltenibart to Novo Nordisk-87
- Week of Nov 3, 2025 · tone 0Omeros (NASDAQ:OMER) vs. Kestra Medical Technologies (NASDAQ:KMTS) Financial Analysis-78
- Week of Feb 2, 2026 · tone 0Short Interest in Omeros Corporation (NASDAQ:OMER) Expands By 24.0%-66
- Week of Jan 12, 2026 · tone 0Omeros' (OMER) "Buy" Rating Reiterated at D. Boral Capital-64
- Week of Dec 15, 2025 · tone +100Omeros (NASDAQ:OMER) Stock Rating Upgraded by Wall Street Zen+63
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Omeros Corporation in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 0 | No headlines |
| Last 30 sessions | 9 | -44 |
| Last 90 sessions | 37 | +2 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Monday, October 19, 2026
2 headlines, average tone -99: 0 positive, 0 neutral and 2 negative. Showing all 2.
- www.rttnews.com · 2 outletsOmeros Stock Falls 12% After EMA Committee Reaffirms Negative Narsoplimab OpinionNegative
- econotimes.com · 1 outletEMA Panel Confirms Recommendation to Refuse Omeros' YartemleaNegative
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Omeros Stock Falls 12% After EMA Committee Reaffirms Negative Narsoplimab Opinion | www.rttnews.com | 2 | Negative |
| EMA Panel Confirms Recommendation to Refuse Omeros' Yartemlea | econotimes.com | 1 | Negative |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 16, 2026
3 headlines, average tone -100: 0 positive, 0 neutral and 3 negative. Showing all 3.
- www.rttnews.com · 1 outletOmeros: CHMP Issues Negative Opinion On Marketing Authorization Application For NarsoplimabNegative
- www.rttnews.com · 1 outletOmeros Receives Second CHMP Rejection For Narsoplimab In Europe; Stock DownNegative
- www.finanznachrichten.de · 1 outletOmeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMANegative
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Omeros: CHMP Issues Negative Opinion On Marketing Authorization Application For Narsoplimab | www.rttnews.com | 1 | Negative |
| Omeros Receives Second CHMP Rejection For Narsoplimab In Europe; Stock Down | www.rttnews.com | 1 | Negative |
| Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA | www.finanznachrichten.de | 1 | Negative |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 12, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletOmeros Corporation (NASDAQ:OMER) Stock Now Rated "Moderate Buy" by Wall Street BrokeragesPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Omeros Corporation (NASDAQ:OMER) Stock Now Rated "Moderate Buy" by Wall Street Brokerages | www.tickerreport.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 2, 2026
1 headline, average tone -99: 0 positive, 0 neutral and 1 negative. Showing all 1.
- www.dailymail.com · 1 outletInside the bitter father-son feud that unravelled the Omeros Bros seafood dynasty - as the tax office winds up the iconic Gold Coast eateryNegative
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Inside the bitter father-son feud that unravelled the Omeros Bros seafood dynasty - as the tax office winds up the iconic Gold Coast eatery | www.dailymail.com | 1 | Negative |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, September 24, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.rttnews.com · 1 outletBiotech Stocks At 52-Week Highs - OMER +13%, TKNO +5%, BLFS, SDGR, INFUPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Biotech Stocks At 52-Week Highs - OMER +13%, TKNO +5%, BLFS, SDGR, INFU | www.rttnews.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Omeros Corporation, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.